
Novel genetic and epigenetic therapeutics for IPF could rebalance this complex genetic instrument when it falls out of tune in old age. Clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 genome editing has already been used in primary airway epithelial cell lines to modify the DSP risk variant. The epigenetic modification also holds promise. Understanding the causes and cures of IPF remains one of the significant challenges of pulmonary medicine. But as the information gels, we move one step closer.
Like
Save
Share